Estrogen Receptor Positive (ER+) Breast Cancer Outlook 2017 Industry Estrogen Receptor Positive (ER+) Breast Cancer | Page 4

Estrogen Receptor Positive (ER+) Breast Cancer -
Treatment Landscape & Competitive Analysis,
2017
Comparative analysis of marketed drugs by therapy, cost of treatment, Therapeutic Class. Coverage of the
Estrogen Receptor Positive (ER+) Breast Cancer Phase III and Pre-registration Drugs Analysis by product type,
molecule type, route of administration, Median Progression Free Survival.
The report reviews key players involved in the therapeutics development for Estrogen Receptor Positive
(ER+) Breast Cancer and also provide market barriers, market drivers and opportunities Provides Phase III
products assessment by line of therapy and target.
Few Points from List of Table and Figures:
List of Tables
Table 1: Stages of Breast Cancer according to the TNM staging system
Table 2: Classification Of Grades of Estrogen Positive Breast Cancer, 2017
Table 3: Percentage of Survival Rates , 2017
Table 4: Chemotherapy Given in ER Positive Breast Cancer, 2017
Table 5: Hormone Therapy Given In ER-Positive Breast Cancer